87 related articles for article (PubMed ID: 9007154)
1. Anemia of cancer: pathogenesis and treatment with recombinant erythropoietin.
Mittelman M
Isr J Med Sci; 1996 Dec; 32(12):1201-6. PubMed ID: 9007154
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
Desai J; Demetri GD
Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
[TBL] [Abstract][Full Text] [Related]
3. [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer].
Lastiri JM; Specterman SR; Rendo P; Pallotta MG; Varela MS; Goldstein S
Medicina (B Aires); 2002; 62(1):41-7. PubMed ID: 11965849
[TBL] [Abstract][Full Text] [Related]
4. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
Monnerat C; Leyvraz S
Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
Nowrousian MR
Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
7. Anemia in multiple myeloma.
Ludwig H; Pohl G; Osterborg A
Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cancer-related anemia.
Badzek S; Curić Z; Krajina Z; Plestina S; Golubić-Cepulić B; Radman I
Coll Antropol; 2008 Jun; 32(2):615-22. PubMed ID: 18756919
[TBL] [Abstract][Full Text] [Related]
10. Anemia in renal insufficiency.
Santoro A
Rev Clin Exp Hematol; 2002; Suppl 1():12-20. PubMed ID: 12735211
[TBL] [Abstract][Full Text] [Related]
11. The blue cross blue shield assessment technology review: summary of findings.
Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
[TBL] [Abstract][Full Text] [Related]
12. The impact and management of anaemia in haematological malignancies.
Coiffier B
Med Oncol; 2000 Nov; 17 Suppl 1():S2-10. PubMed ID: 11188782
[TBL] [Abstract][Full Text] [Related]
13. rHuEPO and improved treatment outcomes: potential modes of action.
Blackwell K; Gascón P; Sigounas G; Jolliffe L
Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
[TBL] [Abstract][Full Text] [Related]
14. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
Beguin Y
Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
[TBL] [Abstract][Full Text] [Related]
15. EPO's alter ego: erythropoietin has multiple actions.
Lappin TR; Maxwell AP; Johnston PG
Stem Cells; 2002; 20(6):485-92. PubMed ID: 12456956
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial experience using erythropoietin during radiation therapy.
Lavey RS
Strahlenther Onkol; 1998 Dec; 174 Suppl 4():24-30. PubMed ID: 9879344
[TBL] [Abstract][Full Text] [Related]
17. rHuEPO and treatment outcomes: the clinical experience.
Hudis CA; Van Belle S; Chang J; Muenstedt K
Oncologist; 2004; 9 Suppl 5():55-69. PubMed ID: 15591423
[TBL] [Abstract][Full Text] [Related]
18. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
19. Cancer-related anemia.
Abdel-Razeq HN
Saudi Med J; 2004 Jan; 25(1):15-20. PubMed ID: 14758372
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]